Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities:~* Follicular lymphoma grade 1 and 2~* Immunocytoma and lymphoplasmocytic lymphoma~* Marginal zone lymphoma, nodal and generalised~* Mantle cell lymphoma~* lymphocytic lymphoma (CLL without leucaemic characteristics)~* non-specified/classified lymphomas of low malignancy~* Recurrent disease (remission duration minimum 3 months), independent of type or quantity of prior therapies, except of Rituximab containing regimens, or if remission duration is \> 1 year after Rituximab containing regimen, or refractory to prior therapy (progression under therapy or during 3 months after completion), except refractory disease to purin analogs or Bendamustine~* Need for therapy, except mantle cell lymphomas~* Stadium II (bulky disease, 7.5 cm), II or IV~* Written informed consent~* Performance status WHO 0-2~* Histology not older than 6 months~Exclusion Criteria:~* Patients not establishing all above mentioned prerequisites~* Option of a primary, potentially curative radiation therapy~* Patients refractory to Rituximab containing regimens~* Comorbidities excluding a study conform therapy:~heart attack during the last 6 months severe, medicinal not adjustable hypertonia severe functional defects of the heart (NYHA III or IV) lung (WHO grade III or IV) liver or kidney (creatinine \> 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma~* Active auto immunohemolytic anemia (AIHA)~* HIV positive patients~* Active hepatitis infection~* Severe psychiatric diseases~* No compliance or non-compliance to be expected~* Pregnant or breast feeding women~* Anamnestic malignancies or secondary malignancies, not proven~* Cured/curable by surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine plus Rituximab (Type: EXPERIMENTAL): Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
- Fludarabine plus Rituximab (Type: ACTIVE_COMPARATOR): Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w

Based on this trial design, predict the completion outcome and termination type (if applicable).